Voglistar GM 2 Forte Tablet SR 1*10

Description

Manufacturer:

Mankind Pharma Ltd

Salt Composition:

Gliclazide, Metformin hydrochloride, Voglibose

Description:

Voglistar GM 2 Forte Tab is combination oral antidiabetic medications used in the management of type 2 diabetes mellitus. They contain a combination of three active ingredients: gliclazide, metformin hydrochloride, and voglibose, each working through different mechanisms to improve glycemic control.

Gliclazide is a sulfonylurea that stimulates the pancreas to release more insulin, thereby lowering blood glucose levels. Metformin hydrochloride is a biguanide that primarily reduces hepatic glucose production (the amount of glucose produced by the liver) and also improves insulin sensitivity (how well the body’s cells respond to insulin). Voglibose is an alpha-glucosidase inhibitor that works in the small intestine to slow down the digestion and absorption of carbohydrates after meals, thus reducing postprandial (after-meal) blood glucose spikes.

The “GM” in the name indicates the presence of gliclazide and metformin, while the number “2” likely refers to the strength of gliclazide (e.g., 2mg). “Forte” typically indicates a higher strength of one or more of the components compared to the regular Voglistar GM 2 Tab. This triple combination approach is often prescribed for patients with type 2 diabetes who require multiple oral agents to achieve adequate blood sugar control when diet and exercise alone, or dual therapy, are insufficient.

By targeting different aspects of glucose metabolism, these medications can provide more comprehensive glycemic management. The specific dosages of each component in Voglistar GM 2 Forte and Voglistar GM 2 will vary, and the choice between the two will depend on the individual patient’s needs and response to treatment, as determined by a healthcare professional.

Common side effects associated with these medications include hypoglycemia (low blood sugar, more likely with gliclazide), gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort (more common with metformin and voglibose, especially initially), and flatulence (with voglibose). Regular monitoring of blood glucose levels and kidney function is essential during treatment. Patients should be educated on the signs and symptoms of hypoglycemia and how to manage it. These medications are prescription drugs and should only be used under the guidance of a qualified healthcare professional.